7 unchanged sentences
Form of Common Stock Certificate.
−Removed: Transition and Separation Agreement, as amended, by and between IDEAYA Biosciences, Inc.
−Removed: and Julie Hambleton.
−Removed: Consulting Agreement by and between IDEAYA Biosciences, Inc.
−Removed: and Julie Hambleton.
−Removed: Collaboration, Option and License Agreement between GlaxoSmithKline Intellectual Property (No.
−Removed: 4) Limited and IDEAYA Biosciences, Inc.
−Removed: dated as of June 15, 2020.
+Added: Amendment No.
+Added: 1 to Clinical Trial Collaboration and Supply Agreement between Pfizer Inc.
+Added: and IDEAYA Biosciences, Inc.
+Added: dated as of September 23, 2020.
Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
9 unchanged sentences
Certain information in this exhibit has been excluded pursuant to Regulation S-K, Item 601(b)(10).
−Removed: Indicates management contract or compensatory plan.
The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of IDEAYA Biosciences, Inc.
2 unchanged sentences
IDEAYA Biosciences, Inc.
−Removed: August 12, 2020
+Added: November 12, 2020
/s/ Yujiro Hata
1 unchanged sentence
(Principal Executive Officer)
−Removed: August 12, 2020
+Added: November 12, 2020
/s/ Paul Stone, J.D.
Paul Stone, J.D.
−Removed: Chief Financial Officer
+Added: Senior Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.